These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 34581321)
41. Asymmetric 1,3-dipolar cycloaddition reaction of nitrones and acrolein with a bis-titanium catalyst as chiral Lewis acid. Kano T; Hashimoto T; Maruoka K J Am Chem Soc; 2005 Aug; 127(34):11926-7. PubMed ID: 16117516 [TBL] [Abstract][Full Text] [Related]
42. The first generation of β-galactosidase-responsive prodrugs designed for the selective treatment of solid tumors in prodrug monotherapy. Legigan T; Clarhaut J; Tranoy-Opalinski I; Monvoisin A; Renoux B; Thomas M; Le Pape A; Lerondel S; Papot S Angew Chem Int Ed Engl; 2012 Nov; 51(46):11606-10. PubMed ID: 22996951 [TBL] [Abstract][Full Text] [Related]
43. Acrolein scavengers: reactivity, mechanism and impact on health. Zhu Q; Sun Z; Jiang Y; Chen F; Wang M Mol Nutr Food Res; 2011 Sep; 55(9):1375-90. PubMed ID: 21714129 [TBL] [Abstract][Full Text] [Related]
44. Photoactivatable prodrugs of highly potent duocarmycin analogues for a selective cancer therapy. Tietze LF; Müller M; Duefert SC; Schmuck K; Schuberth I Chemistry; 2013 Jan; 19(5):1726-31. PubMed ID: 23225610 [TBL] [Abstract][Full Text] [Related]
45. Chemical ionization mass spectrometric determination of acrolein in human breast cancer cells. Kato S; Post GC; Bierbaum VM; Koch TH Anal Biochem; 2002 Jun; 305(2):251-9. PubMed ID: 12054454 [TBL] [Abstract][Full Text] [Related]
46. Antitumour prodrug development using cytochrome P450 (CYP) mediated activation. Patterson LH; McKeown SR; Robson T; Gallagher R; Raleigh SM; Orr S Anticancer Drug Des; 1999 Dec; 14(6):473-86. PubMed ID: 10834269 [TBL] [Abstract][Full Text] [Related]
47. Chemistry and biology of DNA containing 1,N(2)-deoxyguanosine adducts of the alpha,beta-unsaturated aldehydes acrolein, crotonaldehyde, and 4-hydroxynonenal. Minko IG; Kozekov ID; Harris TM; Rizzo CJ; Lloyd RS; Stone MP Chem Res Toxicol; 2009 May; 22(5):759-78. PubMed ID: 19397281 [TBL] [Abstract][Full Text] [Related]
49. A Metal-Polyphenol-Coordinated Nanomedicine for Synergistic Cascade Cancer Chemotherapy and Chemodynamic Therapy. Ren Z; Sun S; Sun R; Cui G; Hong L; Rao B; Li A; Yu Z; Kan Q; Mao Z Adv Mater; 2020 Feb; 32(6):e1906024. PubMed ID: 31834662 [TBL] [Abstract][Full Text] [Related]
50. Bortezomib-catechol conjugated prodrug micelles: combining bone targeting and aryl boronate-based pH-responsive drug release for cancer bone-metastasis therapy. Zhu J; Huo Q; Xu M; Yang F; Li Y; Shi H; Niu Y; Liu Y Nanoscale; 2018 Oct; 10(38):18387-18397. PubMed ID: 30256367 [TBL] [Abstract][Full Text] [Related]
52. Iterative design of emetine-based prodrug targeting fibroblast activation protein (FAP) and dipeptidyl peptidase IV DPPIV using a tandem enzymatic activation strategy. Akinboye ES; Brennen WN; Rosen DM; Bakare O; Denmeade SR Prostate; 2016 Jun; 76(8):703-14. PubMed ID: 26835873 [TBL] [Abstract][Full Text] [Related]
53. Formation of acrolein-derived 2'-deoxyadenosine adduct in an iron-induced carcinogenesis model. Kawai Y; Furuhata A; Toyokuni S; Aratani Y; Uchida K J Biol Chem; 2003 Dec; 278(50):50346-54. PubMed ID: 14522963 [TBL] [Abstract][Full Text] [Related]
54. A novel anticancer theranostic pro-prodrug based on hypoxia and photo sequential control. Feng W; Gao C; Liu W; Ren H; Wang C; Ge K; Li S; Zhou G; Li H; Wang S; Jia G; Li Z; Zhang J Chem Commun (Camb); 2016 Aug; 52(60):9434-7. PubMed ID: 27379361 [TBL] [Abstract][Full Text] [Related]
55. Molecular mechanisms of 4-hydroxy-2-nonenal and acrolein toxicity: nucleophilic targets and adduct formation. LoPachin RM; Gavin T; Petersen DR; Barber DS Chem Res Toxicol; 2009 Sep; 22(9):1499-508. PubMed ID: 19610654 [TBL] [Abstract][Full Text] [Related]
56. Identification of Boronic Acid Derivatives as an Active Form of N-Alkylaminoferrocene-Based Anticancer Prodrugs and Their Radiolabeling with Daum S; Toms J; Reshetnikov V; Özkan HG; Hampel F; Maschauer S; Hakimioun A; Beierlein F; Sellner L; Schmitt M; Prante O; Mokhir A Bioconjug Chem; 2019 Apr; 30(4):1077-1086. PubMed ID: 30768258 [TBL] [Abstract][Full Text] [Related]
57. Quantitative and Site-Specific Chemoproteomic Profiling of Targets of Acrolein. Chen Y; Liu Y; Hou X; Ye Z; Wang C Chem Res Toxicol; 2019 Mar; 32(3):467-473. PubMed ID: 30604966 [TBL] [Abstract][Full Text] [Related]
58. Therapeutic Nanoreactors as In Vivo Nanoplatforms for Cancer Therapy. Mukerabigwi JF; Ge Z; Kataoka K Chemistry; 2018 Oct; 24(59):15706-15724. PubMed ID: 29572992 [TBL] [Abstract][Full Text] [Related]